

[REDACTED]

---

**From:** [REDACTED]  
**Sent:** mercredi 27 septembre 2017 08:40  
**To:** [REDACTED]  
**Cc:** [REDACTED]  
**Subject:** Re: Prescrire's contribution on orphan drugs for SPC study

Dear [REDACTED],  
Thank you for your email and kind contribution which we will send to the contractor and ensure that it is taken into account.  
With kind regards  
[REDACTED]

Sent from [Nine](#)

---

**From:** [REDACTED]  
**Sent:** 27 Sep 2017 08:19  
**To:** [REDACTED]  
**Cc:** [REDACTED]  
**Subject:** Prescrire's contribution on orphan drugs for SPC study

Dear [REDACTED],

Regarding the study on "*the economic impact of SPC, pharmaceutical incentives and rewards in Europe*" currently being carried out by *Copenhagen Economics* on behalf of the European Commission, it was initially foreseen that a representative of Prescrire would be interviewed to provide insight into Prescrire's assessments of orphan drugs authorised by the EMA.

However, such an interview did not take place as Copenhagen Economics were unable to carry out the conversation in French.

You will find attached a series of articles published in *Prescrire International* between 2004 and 2017 which include scientific assessments of more than 50 orphan drugs authorised by the EMA which are still under protection. We would be grateful if you would be so kind as to share these with *Copenhagen Economics* and to ensure that they are duly considered during their study.

Please do not hesitate to contact us should you need any further information or explanation.

With kind regards,

[REDACTED]



[REDACTED]

